Lead Oncology Program

About Lipo-Immuno Tech

Founded in 2020 and based in Cambridge, USA, Lipo-Immuno Tech is a private, pre-clinical stage biotech leveraging a versatile lipid nanoparticle (LNP) delivery platform to create novel immunotherapies. The company is advancing a pipeline of programs targeting solid tumors and infectious diseases, with its lead oncology candidate expected to enter clinical trials in the near term. Its strategy involves both internal development and strategic partnerships to expand the application of its platform. The company is positioned in the high-growth fields of immuno-oncology and mRNA therapeutics, capitalizing on the proven success of LNP technology.

About NuAcRes

NuAcRes is a private, pre-clinical stage biotech developing antibody therapeutics for oncology and autoimmune indications. The company leverages a proprietary technology platform to engineer antibodies with enhanced specificity and functionality. While still in the research and development phase, NuAcRes is positioning itself in the competitive but high-value antibody therapeutics market, with a pipeline of early-stage assets. Its success will depend on successful translation of its platform science into clinical candidates and securing further partnership or investment funding.

Therapeutic Areas

Other Solid Tumors Drugs